The introduction of the sulfonamides in the 1930s and benzylpenicillin in the 1940s completely revolutionized medicine by reducing the morbidity and mortality of many infectious diseases. Today, antimicrobial drugs are used in food-producing animals to treat and prevent diseases and to enhance growth rate and feed efficiency. Such use is fundamental to animal health and well-being and to the economics of the livestock industry, and has seen the development of antimicrobials such as ceftiofur, florfenicol, tiamulin, tilmicosin, tulathromycin, and tylosin specifically for use in food-producing animals. 1,2 However, these uses may result in residues in foods and have been linked to the emergence of antibiotic-resistant strains of diseasecausing bacteria with potential human health ramifications. 3 Antimicrobial drug resistance is not addressed in detail in this text, and the interested reader is referred to an excellent overview by Martinez and Silley. 4 Many factors influence the residue profiles of antibiotics in animal-derived edible tissues (meat and offal) and products (milk and eggs), and in fish and honey. Among these factors are the approved uses, which vary markedly between antibiotic classes and to a lesser degree within classes. For instance, in some countries, residues of quinolones in animal tissues, milk, honey, shrimp, and fish are legally permitted (maximum residue limits [MRLs] have been established). By comparison, the approved uses of the macrolides are confined to the treatment of respiratory disease and for growth promotion (in some countries) in meat-producing animals (excluding fish), and to the treatment of American foulbrood disease in honeybees. As a consequence, residues of macrolides